ClinicalTrialsFinder
RecruitingPhase 1NCT07465653

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of HJB647 in Participants With Chronic Stable Heart Failure With Reduced Ejection Fraction

Sponsor

Novartis Pharmaceuticals

Enrollment

12 participants

Start Date

Mar 18, 2026

Study Type

INTERVENTIONAL

Conditions

Heart Failure With Reduced Ejection Fraction

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HJB647 high dose, a drug called HJB647 low dose, and others for people with heart failure with reduced ejection fraction. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHJB647 low dose

Study drug low dose in capsule form

DRUGHJB647 high dose

Study drug high dose in capsule form

OTHERPlacebo

Placebo control in capsule form

Locations(4)

Synergy Healthcare

Bradenton, Florida, United States

Nature Coast Clinical Research LLC

Inverness, Florida, United States

Jacksonville Center for Clinical

Jacksonville, Florida, United States

Novartis Investigative Site

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07465653

Related Trials

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

NCT065526373 locations

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574199 locations

Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients

NCT076950902 locations

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

NCT065269885 locations

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT072143763 locations